Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Advances in Therapy|February 6, 2025
Road to Hepatitis C Elimination in Israel: Improvements in Linkage to Care (2009-2020)Ayelet A Basson, Clara Weil, Steven E Marx, et al.
Journal of Viral Hepatitis|August 27, 2021
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trialsEdward Gane, Victor de Ledinghen, Douglas E Dylla, et al.
Advances in Therapy|January 12, 2026
Prescribing Patterns and Perceptions of Pancreatic Enzyme Replacement Therapy among Healthcare Providers: A Prospective United States Healthcare Providers SurveyMotaz Ashkar, Jennifer Geremia, Zach Baldwin, et al.
Advances in Therapy|October 27, 2021
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019Nancy Reau, Mark S Sulkowski, Emmanuel Thomas, et al.
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Journal of Viral Hepatitis|August 29, 2022
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohortsJordan J Feld, Xavier Forns, Douglas E Dylla, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus InfectionEli Zuckerman, Julio A Gutierrez, Douglas E Dylla, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Pageof 2